Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roctavian
Biotech
BioMarin axes 4 candidates, centers R&D around 3 assets
BioMarin is prioritizing three of its “most productive” assets, leaving four candidates on the wayside in a move expected to save up to $60 million.
Gabrielle Masson
Apr 25, 2024 10:10am
BioMarin looks to up pace of new drug filings
Sep 12, 2023 3:58pm
FDA OKs companion Dx with BioMarin hemophilia gene therapy
Jun 30, 2023 10:35am
BioMarin lays off 120 employees in bid to save $50M a year
Oct 7, 2022 8:33am